PriceTargets.com logo

AstraZeneca - AZNCF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13,500.00
  • Forecasted Upside: 10,038.18%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$133.16 As of 09/27/2023 01:00 AM ET
▼ -1.79 (-1.33%)

This chart shows the closing price for AZNCF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AstraZeneca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZNCF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZNCF

Analyst Price Target is $13,500.00
▲ +10,038.18% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $13,500.00, with a high forecast of $13,500.00 and a low forecast of $13,500.00. The average price target represents a 10,038.18% upside from the last price of $133.16.

This chart shows the closing price for AZNCF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in AstraZeneca. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/10/2023BarclaysReiterated RatingBuy$13,500.00
(Data available from 9/28/2018 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2023
  • 4 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 12 very negative mentions
Mentions as of
5/1/2023
  • 7 very positive mentions
  • 16 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
Mentions as of
5/31/2023
  • 7 very positive mentions
  • 28 positive mentions
  • 10 negative mentions
  • 8 very negative mentions
Mentions as of
6/30/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
Mentions as of
7/30/2023
  • 3 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
8/29/2023
  • 6 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 6 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AstraZeneca logo
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $133.16
Low: $133.16
High: $137.59

50 Day Range

MA: $137.24
Low: $130.08
High: $147.00

52 Week Range

Now: $133.16
Low: $105.26
High: $153.10

Volume

1,900 shs

Average Volume

3,093 shs

Market Capitalization

N/A

P/E Ratio

163.19

Dividend Yield

3.89%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AstraZeneca?

The following sell-side analysts have issued stock ratings on AstraZeneca in the last year: Barclays PLC.
View the latest analyst ratings for AZNCF.

What is the current price target for AstraZeneca?

1 Wall Street analysts have set twelve-month price targets for AstraZeneca in the last year. Their average twelve-month price target is $13,500.00, suggesting a possible upside of 10,038.2%. Barclays PLC has the highest price target set, predicting AZNCF will reach $13,500.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $13,500.00 for AstraZeneca in the next year.
View the latest price targets for AZNCF.

What is the current consensus analyst rating for AstraZeneca?

AstraZeneca currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZNCF will outperform the market and that investors should add to their positions of AstraZeneca.
View the latest ratings for AZNCF.

What other companies compete with AstraZeneca?

Other companies that are similar to AstraZeneca include Bayer Aktiengesellschaft, Cosmo Pharmaceuticals, CSPC Pharmaceutical Group, Daiichi Sankyo and Dechra Pharmaceuticals. Learn More about companies similar to AstraZeneca.

How do I contact AstraZeneca's investor relations team?

AstraZeneca's physical mailing address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. The company's listed phone number is 442037495000. The official website for AstraZeneca is www.astrazeneca.com. Learn More about contacing AstraZeneca investor relations.